SHIRE 
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
More news
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Susan O’Reilly
BRD | Director/Board Member | - | 19-01-07 |
Dan DeStefano
PRN | Corporate Officer/Principal | - | - |
Leslie Waltke
HRO | Human Resources Officer | - | 12-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Susan O’Reilly
BRD | Director/Board Member | - | 19-01-07 |
| Director/Board Member | - | 19-01-07 | |
Paul Keogh
BRD | Director/Board Member | - | 19-01-07 |
Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows:
- sales of products (95.3%);
- other (4.7%): primarily franchise royalties.
Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B |
